SecBot SecBot
6-K ·Filed Jun 1, 2026

BIOX

Bioceres Crop Solutions Corp.
NEUTRAL
Impact 4/10
Horizonweeks Processed4mo ago SEC0001104659-26-068690
Notable filing: 6-K
Actionable Insight • Neutral

The exchange offer reduces near-term debt maturity pressure at the subsidiary level, a modest credit positive. However, with a $28M market cap and no analyst bullish coverage, the parent company's equity remains highly speculative. Monitor for any parent-level debt restructuring or operational updates in upcoming 20-F filing.

DirectionNeutral
Confidencemedium
Horizonweeks
Final — all horizons settled through T+60d
BIOX ▼ -12.50% at T+60d
NEUTRAL call -12.50% · α vs SPY -13.73% · entry $0.4800 → $0.4200
Entry = T+0 close
Jun 1, 2026
via day close
T+1d
+2.29%
call +2.29% · α +2.15%
$0.4910
settled 5mo ago
T+5d
-12.50%
call -12.50% · α -9.75%
$0.4200
settled 5mo ago
T+20d
-27.06%
call -27.06% · α -25.76%
$0.3501
settled 4mo ago
T+60d
-12.50%
call -12.50% · α -13.73%
$0.4200
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Bioceres Crop Solutions Corp. subsidiary Rizobacter completed an exchange offer and consent solicitation on ~86% of ~$42.7M in outstanding Series IX and X notes, extending maturities as part of broader liability management. This reduces near-term refinancing risk for a key subsidiary but does not address the parent company's $28M market cap or underlying operational performance.

Key Facts

  • Rizobacter completed exchange offer and consent solicitation on May 29, 2026.
  • Participation of ~86% of total outstanding principal amount of Series IX Class A, IX Class B, X Class A, and X Class B notes.
  • Transaction relates to ~US$42.7 million aggregate principal amount of existing notes.
  • Part of Rizobacter's broader liability management and maturity extension efforts.
  • Filing is a 6-K by foreign private issuer Bioceres Crop Solutions Corp. (BIOX).

Financial Impact

~US$42.7 million in notes restructured; 86% participation rate indicates strong creditor support for maturity extension.

debtliquidity

Risk Factors

  • Exchange offer details (new terms, maturity extension length) not disclosed; may involve higher interest costs or dilution.
  • Parent company's small market cap and lack of analyst support suggest limited equity upside from subsidiary-level debt management.
  • Argentine macroeconomic and currency risks for Rizobacter's operations.

Market Snapshot

Exchange
Nasdaq
Sector
Agricultural Chemicals
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Materials & Mining

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001104659-26-068690
Document: 0001104659-26-068690-index-headers.html0001104659-26-068690
Document: 0001104659-26-068690-index.html0001104659-26-068690
Document: 0001104659-26-068690.txt0001104659-26-068690
3 reports for BIOX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for BIOX — sortable, filterable
TypeNow
Sep 21, 2026
5w ago
6-K
BEARISH ★ 6/10
$0.3590 $0.2551▲ +28.94%▲ +28.03%$0.2030 (+43.45%)
Jun 22, 2026
18w ago
6-K
BEARISH ★ 7/10
$0.3796 $0.3501▲ +7.77%▲ +7.62%$0.2030 (+46.52%)
Jun 1, 2026
21w ago
6-K
NEUTRAL ★ 4/10
$0.4800 $0.3501▼ −27.06%▼ −25.76%$0.2030 (−57.71%)
Showing 3 of 3

US Market Status

Market Closed — Opens Tue (16h 40m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026